SCHEMBL92806

SCHEMBL92806

O=CON1C(=O)CCC1=O

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PARL Q9H300 2/20 0.35
ALOX12 P18054 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18510179 1.00 PARL (0.35) PARLALOX12
Formaldehyde SCHEMBL15307446 0.95 PARL (0.33) PARL
SCHEMBL21427229 0.89 BRD4 (0.33)
SCHEMBL18875534 0.83 PARL (0.31) PARL
SCHEMBL12832045 0.83 PARL (0.31) PARL
SCHEMBL12019203 0.78 PARL (0.33) PARL
SCHEMBL14571852 0.78 PARL (0.33) PARL
SCHEMBL9123590 0.74 PARL (0.34) PARLALOX12
SCHEMBL182701 0.71 PARL (0.39) PARLALOX12
SCHEMBL8348981 0.71 PARL (0.39) PARLALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1732 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720075-A1 TOPOISOMERASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF NJ Bio, Inc. (US) 2026-04-08 EP claimed
US-20260022127-A1 HEXACYCLIC TOPOISOMERASE INHIBITORS HAVING CYTOTOXIC ACTIVITY ON CANCER CELLS NJ BIO INC (US) 2026-01-22 US claimed
EP-4558506-A1 HEXACYCLIC TOPOISOMERASE INHIBITORS HAVING CYTOTOXIC ACTIVITY ON CANCER CELLS NJ Bio, Inc. (US) 2025-05-28 EP claimed
CN-119587474-A Liver-targeted chemotherapeutic drug nano micelle preparation method, chemotherapeutic drug and application 中国人民解放军新疆军区总医院 2025-03-11 CN claimed
WO-2024248944-A1 TOPOISOMERASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF NJ BIO, INC. (US) 2024-12-05 WO claimed
US-12076416-B2 Gene editing nanocapsule and preparation method and use thereof HENAN UNIVERSITY (CN) 2024-09-03 US claimed
EP-4371662-A1 METHOD FOR ANALYZING REACTIVE LOW-MOLECULAR-WEIGHT COMPOUND CONTAINED IN POLYOXYETHYLENE DERIVATIVE NOF Corporation (JP) 2024-05-22 EP claimed
US-11945882-B2 Method for producing antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-04-02 US claimed
CN-116790136-B Carboxylic acid succinimide ester dye and reactive dyeing method thereof 现代纺织技术创新中心(鉴湖实验室) 2024-04-02 CN claimed
WO-2024020536-A1 HEXACYCLIC TOPOISOMERASE INHIBITORS HAVING CYTOTOXIC ACTIVITY ON CANCER CELLS NJ BIO, INC. (US) 2024-01-25 WO claimed
EP-0263657-B1 POLYSUBSTITUTED ARYL ACRIDINIUM ESTERS Ciba Corning Diagnostics Corp. (US) 1992-05-13 EP claimed
EP-0460026-A1 HIGH PERFORMANCE AFFINITY CHROMATOGRAPHY COLUMN COMPRISING NON-POROUS, MONODISPERSE POLYMERIC PACKING MATERIAL EASTMAN KODAK COMPANY (US) 1991-12-11 EP claimed
WO-1990009832-A1 HIGH PERFORMANCE AFFINITY CHROMATOGRAPHY COLUMN COMPRISING NON-POROUS, MONODISPERSE POLYMERIC PACKING MATERIAL EASTMAN KODAK COMPANY (US) 1990-09-07 WO claimed
US-4927769-A OXIDIZING AN ACRIDINIUM ESTER IN THE PRESENCE OF A CATIONIC SURFACTANT, NONIONIC SURFACTANT OR SULFATED PRIMARY ALCOHOL CIBA CORNING DIAGNOSTICS CORP. (US) 1990-05-22 US claimed
US-4774339-A TRACERS; IMMUNOASSAY; FLUORESCENT DYES MOLECULAR PROBES, INC. (US) 1988-09-27 US claimed
EP-0134225-B1 NEW ALKYL DIAMINE DERIVATIVES ALKALOIDA VEGYéSZETI GYáR (HU) 1988-08-17 EP claimed
EP-0071926-B1 NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-10-08 EP claimed
EP-0134225-A1 NEW ALKYL DIAMINE DERIVATIVES. ALKALOIDA VEGYESZETI GYAR (HU) 1985-03-20 EP claimed
WO-1984002907-A1 NEW ALKYL DIAMINE DERIVATIVES ALKALOIDA VEGYESZETI GYAR (HU) 1984-08-02 WO claimed
EP-0071926-A1 New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-02-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022127-A1 HEXACYCLIC TOPOISOMERASE INHIBITORS HAVING CYTOTOXIC ACTIVITY ON CANCER CELLS TOP1, TOP2A, TOP2B PARL 4754/4885ALOX12 3191/4885
US-12076416-B2 Gene editing nanocapsule and preparation method and use thereof RNASE1, LDLR, CASK PARL 1291/4885ALOX12 1107/4885
US-11945882-B2 Method for producing antibody-drug conjugate UGT1A9, ALB, MRPL21 PARL 4624/4885ALOX12 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.